India Pharma Outlook 2016 - Growth from Exports and Domestic Getting Better along with Implementation of Policies under Make-in-India Policies -- Research and Markets

DUBLIN, March 31, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "India Pharma Outlook 2016" report to their offering.

2016 will be a crucial time for drug makers and consumers. During Make-in-India' week in Mumbai, the government highlighted many amendments and introduced new policies with an aim to make India a major hub for end to end drug discovery. To boost drug discovery, to promote manufacturing of certain drugs against life threatening diseases like AIDS, and to reduce India's dependence on China, the government has promised many incentives (exemption from excise duty or tax) and also plans to set up venture capital funds and cluster developments to strengthen pharma infrastructure and business.

Other developments or initiatives include:

i) The voluntary Uniform code of Pharma marketing practice will be replaced with a mandatory code by June. This will stop the promotion of drugs prior to receipt of the marketing approval and also the practice of drug makers offering gifts to doctors upon prescribing their products

ii) Concept of the Online pharmacies' is also expected to be implemented during this year

iii) Change in FDI rule where investors now invest through automatic route rather than undergoing any prior regulatory approval

iv) Growth in Medical Infrastructure which will increase accessibility to drug market to improve in Tier-II towns and rural areas.

Gowth in bulk drugs declined due to regulatory scrutiny and rising competition & market factors from other Asian competing nations, but it will be compensated by geographies expansion (e.g., Lupin, Cipla, Sun pharma) and sustainable growth from the domestic formulation (e.g. Alkem, Cipla, Sun pharma, Dr Reddy), mainly from the chronic diseases' segment, due to growth in urban population, better awareness of healthcare, and greater penetration of services. India's pharma sector has started expanding into other regulated markets (Japan, Germany, France, Canada) and Tier-II countries (Brazil, Mexico, Venezuela, Russia, etc.).

To explore further opportunities of growth, Indian pharma companies have started developing complex generics/ biosimilars. Almost all companies, among Top-20 list, have robust pipeline in this value chain, targeting primarily emerging markets; however, they are also capitalizing on their competitiveness and capabilities to enter into the regulated market.

Key Topics Covered:

1. Aurobindo Pharma - US BUSINESS AND INJECTABLES KEYS TO GROWTH - Looking to strengthen in other regions

2. CADILA HEALTHCARE LTD: Future growth from NCE, Bio-Similars, Vaccines, Transdermal and Complex Generics

3. Cipla Ltd: Consolidation of Recent Acquisitions + Geographic Expansion of the Inhaler Business

4. LUPIN LIMITED :Potential of Complex Generics and Gavis Integration Yet to Unfold

5. NATCO PHARMA: Leading Oncology Company In India - Targeting US market with less competitive and high complex Drugs

Companies Mentioned

- Aurobindo

- Cadila Healthcare

- Cipla

- Dr. Reddy's

- Lupin

- Natco

For more information visit http://www.researchandmarkets.com/research/zq85gb/india_pharma

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]